Everence Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Everence Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,090	Closed	-$253K	–	893
2025 Q4	$253K	Hold	5,090	–	–	0.02%	660
2025 Q3	$243K	Buy	+5,090	New	+$205K	0.01%	691
2025 Q1	–	Sell	-5,620	Closed	-$203K	–	840
2024 Q4	$203K	Sell	5,620 -1,950	-26%	-$68.7K	0.01%	780
2024 Q3	$236K	Hold	7,570	–	–	0.01%	679
2024 Q2	$228	Hold	7,570	–	–	0.02%	644
2024 Q1	$258	Hold	7,570	–	–	0.02%	618
2023 Q4	$219K	Hold	7,570	–	–	0.02%	674
2023 Q3	$209	Hold	7,570	–	–	0.02%	661
2023 Q2	$251K	Hold	7,570	–	–	0.02%	580
2023 Q1	$274	Hold	7,570	–	–	0.02%	573
2022 Q4	$270	Hold	7,570	–	–	0.02%	587
2022 Q3	$256K	Buy	+7,570	New	+$246K	0.02%	570
2022 Q2	–	Sell	-8,430	Closed	-$272K	–	763
2022 Q1	$272K	Buy	+8,430	New	+$258K	0.02%	587
2021 Q3	–	Sell	-10,380	Closed	-$320K	–	765
2021 Q2	$320K	Hold	10,380	–	–	0.03%	550
2021 Q1	$272K	Hold	10,380	–	–	0.02%	591
2020 Q4	$261K	Hold	10,380	–	–	0.03%	563
2020 Q3	$216K	Hold	10,380	–	–	0.02%	563
2020 Q2	$250K	Hold	10,380	–	–	0.03%	512
2020 Q1	$187K	Buy	+10,380	New	+$218K	0.03%	528
2019 Q3	–	Sell	-7,020	Closed	-$232K	–	662
2019 Q2	$232K	Hold	7,020	–	–	0.04%	506
2019 Q1	$246K	Buy	+7,020	New	+$261K	0.04%	474
2018 Q3	–	Sell	-3,420	Closed	-$205K	–	450
2018 Q2	$205K	Buy	+3,420	New	+$177K	0.04%	402

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Everence Capital Management's SUPN Position: Q1 2026 in Review

Everence Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 5,090 shares — an estimated $253K sold.

Everence Capital Management first reported a position in SUPN in Q2 2018 and held it in 22 quarters. The position peaked at $320K in Q2 2021. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Everence Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Everence Capital Management sold 5,090 Supernus Pharmaceuticals shares in Q1 2026, an estimated $253K.
Everence Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 22 quarters.
Everence Capital Management's Supernus Pharmaceuticals position peaked at $320K in Q2 2021.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.